ClinicalTrials.gg
RecruitingNCT06492720Updated Apr 9, 2026

A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

An interventional study of Focused ultrasound (FUS) treatment in Drug Resistant Epilepsy, Epilepsy and Epilepsy, Temporal Lobe, sponsored by NaviFUS Corporation. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by NaviFUS Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This will be a prospective, pilot, open-label, two-arm, parallel-group, randomized study to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant epilepsy (DRE).

Read the detailed description

The study aims to demonstrate the efficacy and safety of LIFU neuromodulation in DRE patients, showing its ability to decrease targeted neuronal activity and alleviate epileptic seizures.

Drug-resistant epilepsy (at least 3 anti-seizure medication failed) patients whose epileptogenic foci have been determined by comprehensive presurgical evaluation and meet all eligibility criteria may participate in this study by providing informed consent. Eligible patients will undergo a 8-week baseline observation screening period and will be asked to keep a 8-week seizure diary. This diary will serve as a baseline prior to treatment and will continue to be recorded throughout the treatment and follow-up period.

This study will enroll a maximum of 16 eligible patients. Eligible patients will be randomized into two groups to receive three-consecutive 5-minute twice (low dose group) or three-consecutive 10-minute FUS treatment twice (high dose group) in a week using assigned ultrasound exposure doses generated by the NaviFUS System. Following treatment, there will be a 24-week follow-up period. Patients will be allowed concomitant use of anti-seizure medications (ASMs) throughout the whole study period.

02

Conditions studied

  • Drug Resistant Epilepsy
  • Epilepsy
  • Epilepsy, Temporal Lobe
  • Seizures, Focal

Keywords

  • NaviFUS System
  • Focused Ultrasound
  • Low-Intensity Focused Ultrasound
  • LIFU
03

In context

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

This study's planned enrollment of 16 is below the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

NaviFUS Corporation is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged over than and equal to 18 years old.
  2. Patients with drug-resistant epilepsy (defined as at least 3 ASM failed) and 1-4 ASM at the time of study entry.
  3. Epileptogenic focus (or foci) is determined by comprehensive presurgical evaluation.
  4. At least 4 focal-onset seizures with objectively visible or significantly disabling manifestations in the 8-week baseline and at least one seizure per month in the baseline.
  5. Willing and able to sign written and be able to comply with the study protocol during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Patients with concurrent active psychiatric or mood disorders that have been assessed to interfere with participation in the study.
  2. Presence of pacemaker, implantable cardioverter-defibrillator (ICD), permanent medication pumps, cochlear implants, or deep brain stimulation (DBS).
  3. The skull bone area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), wounds, or atrophy of the scalp.
  4. Image documented calcified lesion in the FUS exposure path.
  5. Abnormal coagulation profile:

    1. (PLT) \< 100,000/μL.
    2. (PT) > 15 sec.
    3. activated partial thromboplastin time (APTT) > 45 sec.
    4. international normalized ratio (INR) > 1.5.
    5. Patients requiring anticoagulant medications.
  6. Pregnant or breast-feeding women.
  7. Coexisting medical problems of sufficient severity to limit compliance with the study.
  8. Known sensitivity/allergy to Magnetic Resonance Imaging (MRI) contrast agents or any of its components; having metallic implants that are assessed as unsuitable for MRI examination.
  9. Use of any recreational drugs or history of drug addiction or known history of substance or alcohol abuse.
  10. Patients have received an drug or an investigational device within 4 weeks prior to the study
  11. Any other condition that, in the investigator's judgment, might affect study endpoints or might increase the risk to the patients or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
  12. Any ASM treatment change during the baseline (screening period).
  13. Vagus nerve stimulation (VNS) dosing changes within 2 months before baseline (screening period).
  14. Radiofrequency thermocoagulation (RFTC) within 2 months before baseline (screening period).
  15. Patient has an IQ \< 70, based on the Wechsler Abbreviated Scale of Intelligence (WASI-III or IV).
  16. Any other condition that, in the investigator's judgment, patient not applicable to participate this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Low dose group FUS treatment

    FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.

    Device: Focused ultrasound (FUS) treatment

  • Experimental
    High dose group FUS treatment

    FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: three consecutive 10-minute FUS exposures with two 5-minute intermission intervals.

    Device: Focused ultrasound (FUS) treatment

Interventions

  • DeviceFocused ultrasound (FUS) treatment

    The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.

06

What researchers measure

Primary outcomes

  1. Changes of seizure frequency after treatment compared to baseline

    The changes in patient's seizure frequency from baseline through the study completion will be assessed based on the seizure diaries.

    Time frame: up to 33 weeks

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The incidence and severity of AEs associated with LIFU neuromodulation in patients with DRE.

    Time frame: up to 33 weeks

  2. Responder rate (≧50% seizure reduction)

    The changes in responder rate (≧50% seizure reduction) from baseline through the study completion will be assessed based on the seizure diaries.

    Time frame: up to 33 weeks

  3. Change from baseline in number of seizure-free days

    The changes in number of seizure-free days from baseline through the study completion will be assessed based on the seizure diaries.

    Time frame: up to 33 weeks

  4. Change from baseline in subjective seizure strength

    The changes in subjective seizure strength from baseline through the study completion will be assessed based on the seizure diaries.

    Time frame: up to 33 weeks

  5. Quality of Life in Epilepsy (QOLIE-31)

    The QOLIE-31 is a survey of health-related quality of life for adults with epilepsy. There are 31 questions about patient's health and daily activities. The total score is calculated as a weighted mean of the sub-scale scores and the scoring of the QOLIE-31 requires the conversion of raw data to a scale of 0 to 100 for each sub-scale, with higher scores reflecting higher quality of life.

    Time frame: up to 33 weeks

  6. Changes of Beck Anxiety Inventory (BAI) after treatment compared to baseline

    BAI is a 21-question multiple-choice self-report inventory that is used to measure the severity of anxiety. Each answer is scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms.

    Time frame: up to 33 weeks

  7. Changes of Beck Depression Inventory (BDI) after treatment compared to baseline

    BDI-II, a 21-question multiple-choice self-report inventory, is a psychological test used to measure the severity of depression. Each answer is rated on a scale of 0 (none at all) to 3 (severe). Higher total scores indicate more severe depressive symptoms.

    Time frame: up to 33 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chen SG, Tsai CH, Lin CJ, Lee CC, Yu HY, Hsieh TH, Liu HL. Transcranial focused ultrasound pulsation suppresses pentylenetetrazol induced epilepsy in vivo. Brain Stimul. 2020 Jan-Feb;13(1):35-46. doi: 10.1016/j.brs.2019.09.011. Epub 2019 Sep 24. PubMed 31575487 ↗
  • Chu PC, Yu HY, Lee CC, Fisher R, Liu HL. Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model. Neurotherapeutics. 2022 Jul;19(4):1368-1380. doi: 10.1007/s13311-022-01250-7. Epub 2022 May 17. PubMed 35581489 ↗
  • Lee CC, Chou CC, Hsiao FJ, Chen YH, Lin CF, Chen CJ, Peng SJ, Liu HL, Yu HY. Pilot study of focused ultrasound for drug-resistant epilepsy. Epilepsia. 2022 Jan;63(1):162-175. doi: 10.1111/epi.17105. Epub 2021 Nov 2. PubMed 34729772 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 102 interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 50. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 9, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06492720
Lead sponsor
NaviFUS Corporation
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Sep 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Sheang-Tze Fung, Ph.D.
Contact
stfung@navifus.com
02-25860560 ext. 167
Arthur Lung, Ph.D.
Contact
arthur.lung@navifus.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion